CLSD Insider Trading Activity and SEC Form 4 Filings
CLSD insider trading summary
No open-market insider purchases or sales of Clearside Biomedical, Inc. (CLSD) have been reported on SEC Form 4 in the past 12 months.
Latest CLSD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 24, 2025 | Clay Thorp | Insider | Buy | $14K (15,000 @ $0.92) |
| Nov 1, 2024 | Ngai Hang Victor Chong | Chief Medical Officer | Buy | $37K (36,500 @ $1.00) |
| Jun 24, 2024 | Ngai Hang Victor Chong | Chief Medical Officer | Buy | $25K (23,500 @ $1.06) |
| May 15, 2024 | Benjamin R Yerxa | Insider | Buy | $10K (7,813 @ $1.31) |
| Apr 18, 2024 | Anthony S Gibney | Insider | Buy | $121K (93,290 @ $1.30) |
| Apr 17, 2024 | Anthony S Gibney | Insider | Buy | $8K (6,710 @ $1.25) |
| Mar 20, 2024 | Ngai Hang Victor Chong | Chief Medical Officer | Buy | $48K (30,000 @ $1.60) |
| Feb 7, 2024 | Bradford T Whitmore | 10% Owner | Buy | $600K (444,444 @ $1.35) |
| Jan 19, 2024 | George M Lasezkay | CEO | Sell | $23K (18,000 @ $1.27) |
| Jan 19, 2024 | Charles A. Deignan | Chief Financial Officer | Sell | $17K (12,900 @ $1.28) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.